跳至主要内容
临床试验/IRCT20200510047383N1
IRCT20200510047383N1招募中3 期

Evaluation of the effect of Tocilizumab on outcomes of the severe COVID-19, determining indications within the paradigm of host-directed therapy

Arak University of Medical Sciences0 个研究点目标入组 100 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • COVID-19 disease confirmed by chest ct and PCR
  • No pregnancy
  • No breastfeeding
  • Negative PPD
  • No bacterial pneumonia (negative sputum and urine culture)
  • Not use of atorvastatin , alprazolam , amlodipine , MTX , hydroxychloroquine ,
  • Informed consent

排除标准

  • Disapproval of covid-19 disease by chest computed tomography and PCR
  • Positive PPD
  • Bacterial pneumonia (negative sputum and urine culture)
  • Breastfeeding
  • Use of atorvastatin , alprazolam , amlodipine , MTX , hydroxychloroquine by the patient
  • Lack of Informed consent

研究者

相似试验